Fundraising Fox
Eureka Therapeutics
Emeryville, US · Delaware corporation · 4 known investors
Find your way into Eureka Therapeutics
Sign up to see every warm intro you have to Eureka Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Eureka Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Eureka Therapeutics is a clinical-stage biopharmaceutical company developing T-cell-based therapies to treat solid tumors and other cancers. Its pipeline is built on the ARTEMIS and E-ALPHA technology platforms aimed at targeting cancer-specific antigens.
Founders & leadership
Board
SC
Sandy ChauBoard director
HK
Hsing KungBoard director
QF
Qiushi FuBoard director
CC
MC
Michael CannonBoard director
Investors · 4
Acorn Pacific Ventureslisted by Acorn Pacific VenturesSan Mateo
How we know: board seat on SEC Form D · press coverage · Not right? Tell us
CloudStone Capitallisted by CloudStone CapitalSan Mateo
How we know: CloudStone Capital's portfolio page · Not right? Tell us
GP Capitalreported
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$112.6M disclosed across 4 of 5 rounds · 2014–2023
▶$20MofferedMay 2023 · BiotechnologyRule 506(b)
▶$20MofferedMay 2023 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vivien ChanExecutive Officer
- Cheng LiuExecutive Officer, Director
- Michael CannonDirector
- Marvin SamsonDirector
- William S. Solari IIIDirector
- "Wai-Yan ""Sandy""" ChauDirector
- Reed JobsDirector
- Victor ShumExecutive Officer
- Jacqueline NorthcutDirector
- "Chih-Kai ""C.K." ChengDirector
- Offering amount
- $20M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$45MraisedJan 2020 · 20 investors · BiotechnologyRule 506(b)
▶$45MraisedJan 2020 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jacqueline S. NorthcutDirector
- Marvin T. SamsonDirector
- William S. Solari IIIDirector
- Victor ShumExecutive Officer
- Vivien ChanExecutive Officer
- Cheng LiuExecutive Officer, Director
- Michael D. CannonDirector
- "Wai-Yan ""Sandy""" ChauDirector
- "Chih-Kai ""C.K.""" ChengDirector
- Bo FengDirector
- Offering amount
- $45M
- Amount sold
- $45M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedJun 2018 · 2 investors · BiotechnologyRule 506(b)
▶$20MraisedJun 2018 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher LehmanExecutive Officer
- Bo FengDirector
- Lewis T. WilliamsDirector
- "Chih-Kai ""C.K.""" ChengDirector
- Michael D. CannonDirector
- Bijan NejadnikExecutive Officer
- Wiliam S. Solari IIIDirector
- Victor ShumExecutive Officer
- "Wai-Yan ""Sandy""" ChauDirector
- Cheng LiuExecutive Officer, Director
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$26.6MraisedMay 2017 · 40 investors · BiotechnologyRule 506(b)
▶$26.6MraisedMay 2017 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sandy ChauDirector
- Cheng LiuExecutive Officer, Director
- Hsing KungDirector
- Qiushi FuDirector
- Michael CannonDirector
- Chih-Kai ChengDirector
- Offering amount
- $60M
- Amount sold
- $26.6M
- Minimum investment
- $5K
- First sale
- Dec 2016
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$21MraisedSep 2014 · 28 investors · BiotechnologyRule 506(b)
▶$21MraisedSep 2014 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Hsing KungDirector
- Qiushi FuDirector
- Sandy ChauDirector
- Chih-Kai ChengDirector
- Cheng LiuExecutive Officer, Director
- Offering amount
- $21M
- Amount sold
- $21M
- Minimum investment
- $10K
- First sale
- Aug 2014
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Eureka Therapeutics do?
- Eureka Therapeutics is a clinical-stage biopharmaceutical company developing T-cell-based therapies to treat solid tumors and other cancers. Its pipeline is built on the ARTEMIS and E-ALPHA technology platforms aimed at targeting cancer-specific antigens.
- Who founded Eureka Therapeutics?
- Eureka Therapeutics was founded by Cheng Liu.
- Who are Eureka Therapeutics's investors?
- Eureka Therapeutics's investors include Acorn Pacific Ventures, CloudStone Capital, GP Capital, Yosemite.
- How much funding has Eureka Therapeutics raised?
- Eureka Therapeutics has disclosed $112.6M raised across 4 of its 5 known rounds.
- Where is Eureka Therapeutics headquartered?
- Eureka Therapeutics is headquartered in Emeryville, US.